drugset / Trial / NCT04414540
Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine anti-tumor activity by measuring overall response rate in recurrent and/or metastatic HNSCC patients receiving the combination of metformin and pembrolizumab.
Timeline
- Start
- 2020-08-31
- Primary completion
- 2026-02-02
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 2000 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |